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A B S T R A C T
Trypanothione (T(SH)2) is the main antioxidant metabolite for peroxide reduction in Trypanosoma cruzi;
therefore, its metabolism has attracted attention for therapeutic intervention against Chagas disease. To validate
drug targets within the T(SH)2 metabolism, the strategies and methods of Metabolic Control Analysis and kinetic
modeling of the metabolic pathway were used here, to identify the steps that mainly control the pathway fluxes
and which could be appropriate sites for therapeutic intervention. For that purpose, gamma-glutamylcysteine
synthetase (γECS), trypanothione synthetase (TryS), trypanothione reductase (TryR) and the tryparedoxin cy-
tosolic isoform 1 (TXN1) were separately overexpressed to different levels in T. cruzi epimastigotes and their
degrees of control on the pathway flux as well as their effect on drug resistance and infectivity determined. Both
experimental in vivo as well as in silico analyses indicated that γECS and TryS control T(SH)2 synthesis by
60–74% and 15–31%, respectively. γECS overexpression prompted up to a 3.5-fold increase in T(SH)2 con-
centration, whereas TryS overexpression did not render an increase in T(SH)2 levels as a consequence of high
T(SH)2 degradation. The peroxide reduction flux was controlled for 64–73% by TXN1, 17–20% by TXNPx and
11–16% by TryR. TXN1 and TryR overexpression increased H2O2 resistance, whereas TXN1 overexpression
increased resistance to the benznidazole plus buthionine sulfoximine combination. γECS overexpression led to an
increase in infectivity capacity whereas that of TXN increased trypomastigote bursting. The present data sug-
gested that inhibition of high controlling enzymes such as γECS and TXN1 in the T(SH)2 antioxidant pathway
may compromise the parasite's viability and infectivity.
1. Introduction
Trypanosoma cruzi is the etiological agent of human Chagas disease.
The World Health Organization estimates that 6–7 million people
mainly in the Americas are infected with this parasitic protist, with
≈7500 annual deaths, whereas ≈70 million persons are at risk of be-
coming infected because of living in endemic regions [1,2,63,64].
Moreover, the disease has now also been found in non-endemic coun-
tries due to emigration of infected persons, with consequent non-vec-
torial transmission [2,3].
The current drugs available to treat the infection, benznidazol (Bnz)
and nifurtimox have several drawbacks such as (i) high toxicity which
causes severe side effects [4]; (ii) their lack of efficacy in the treatment
of the chronic stage of infection [5]; and (iii) poor medical infra-
structure: less than 1% of infected people have access to diagnostics and
treatment [65]. Therefore, there is a need for new therapeutic strate-
gies, safer and affordable drugs and validated drug-targets against
Chagas disease [6,7]. Indeed, many T. cruzi enzymes and processes have
been proposed as drug targets [7], including the trypanothione-de-
pendent antioxidant pathway [8–11].
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Trypanothione (T(SH)2) is a conjugate of two glutathione (GSH) and
one spermidine (Spd) molecules that replaces the antioxidant functions
that GSH has in most cells, including mammalian ones [12]. The anti-
oxidant system of T. cruzi is constituted by two modules, the T(SH)2-
synthesis pathway (Fig. 1A) and the T(SH)2-dependent hydroperoxide
reduction pathway (Fig. 1B). In the first one, cysteine (Cys) and glu-
tamate (Glu) are covalently linked by gamma-glutamylcysteine syn-
thetase (γECS) to form gamma-glutamylcysteine (γEC), which then is
bound to glycine (Gly) by glutathione synthetase (GS) thus producing
GSH. The other precursor, Spd, can be imported from the extracellular
environment or can also be synthesized from putrescine (Put) and
decarboxylated S-adenosylmethionine (dAdoMet) by spermidine syn-
thase (SpdS). Finally, trypanothione synthetase (TryS) synthesizes
T(SH)2 by binding two GSH molecules to a Spd molecule [8].
The cytosolic enzymes belonging to the main hydroperoxide re-
duction pathway catalyze peroxide reduction and oxidized trypa-
nothione (TS2) reduction. Firstly, T(SH)2 reduces tryparedoxin 1
(TXN1), which then transfers its electrons to either tryparedoxin per-
oxidase (TXNPx), which has preference for H2O2 and short-chain alkyl/
aryl hydroperoxide reduction, or to a TXN1-dependent non-selenium
glutathione peroxidase-like enzyme (GPx), which has preference for
long-chain alkyl peroxides, although it also uses other peroxides with
one order of magnitude lower affinity [13,14]. These reactions produce
oxidized trypanothione (TS2), which is regenerated by trypanothione
reductase (TryR) using NADPH [8].
The arguments supporting the notion that T(SH)2 metabolism en-
zymes may serve as drug targets are: (i) TryS, TXN, TXNPx and TryR
have no counterparts in the host; (ii) through gene expression manip-
ulation, all the pathway enzymes (Fig. 1) have been proved to be es-
sential in Trypanosoma brucei and Leishmania spp. (reviewed in
[8,11,15]); (iii) TryR, the most intensively studied enzyme for drug-
target design and screening studies, seems to be druggable [16–18]; (iv)
TryS as well as mitochondrial and cytosolic TXNPx's have been pro-
posed as virulence factors [19–21]. Nevertheless, their metabolic vali-
dation as potential sites for therapeutic intervention is still a pending
experimental issue. In this regard, an approach is to determine the role
that each enzyme has in controlling the T(SH)2 metabolism pathway,
because inhibition of the most controlling pathway enzymes would
affect more the pathway function than inhibition of enzymes exerting
limited control (for a review see [22,23].
Metabolic control analysis (MCA) is a theoretical and experimental
framework in the study of the control and regulation of metabolic
Abbreviations
Cys cysteine
Glu glutamate
γEC gamma-glutamylcysteine
Gly glycine
GSH glutathione
Spd spermidine
Put putrescine
AdoMet S-adenosyl methionine
dAdoMet decarboxylated S-adenosyl methionine
T(SH)2 reduced trypanothione
TS2 oxidized trypanothione
ROOH hydroperoxide
γECS gamma-glutamylcysteine synthetase
GS glutathione synthetase
TryS trypanothione synthetase
SpdS spermidine synthase
AdoMetDC S-adenosyl methionine decarboxylase
PutT putrescine transporter
SpdT spermidine transporter
TryR trypanothione reductase
TXN1 tryparedoxin isoform 1
TXNPx tryparedoxin peroxidase
GPx non-selenium glutathione peroxidase-type tryparedoxin
peroxidase
OE overexpressing
CJai flux control coefficient
t-butOOH tert-butyl hydroperoxide
Wt wild type
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Fig. 1. T. cruzi antioxidant pathway. (A) The trypa-
nothione synthesis pathway starting from intracellular
Cys. (B) The TXN1-dependent hydroperoxide reduction
pathway. Metabolites are: Cys, cysteine; Glu, glutamate;
γEC, gamma-glutamyl cysteine; Gly, glycine; GSH, glu-
tathione; Spd, spermidine, Put, putrescine; AdoMet, S-
adenosyl methionine; dAdoMet, decarboxylated S-ade-
nosyl methionine; T(SH)2, reduced trypanothione; TS2,
oxidized trypanothione; ROOH, hydroperoxide.
Transporters and enzymes are: γECS, gamma gluta-
mylcysteine synthetase; GS, glutathione synthetase; TryS,
trypanothione synthetase; SpdS, spermidine synthase;
AdoMetDC, S-adenosyl methionine decarboxylase; PutT
putrescine transporter; SpdT, spermidine transporter;
TryR, trypanothione reductase; TXN1, tryparedoxin 1;
TXNPx, tryparedoxin peroxidase; GPx, glutathione per-
oxidase-type tryparedoxin peroxidase.
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pathways [24,25]; it can be applied to identify suitable drug targets in
the intermediate metabolism of parasites [22,23]. Experimental MCA
studies in several microorganisms and mammalian cells have demon-
strated the non-existence of only one “rate-limiting” or “bottle neck”
enzyme in metabolic pathways. Instead, they have shown that control
of a metabolic pathway flux is shared among all the pathway enzymes/
transporters, with only a few (2–3) steps showing the highest control
[24,25]. MCA allows to quantitatively determine the degree in which a
metabolic pathway flux depends on the activity of each individual
pathway step, a value called flux control coefficient (CJai), where J is the
pathway flux and ai is the activity of the pathway enzyme i. The sum of
the positive CJai (steps that favor the pathway flux) and the negative CJai
(flux-draining steps, e.g. pathway leaks) of all the pathway components
should add up to one (summation theorem). An enzyme/transporter
with a CJai approaching to one means that it has a predominant (but not
unique) role in determining the pathway flux, whereas enzymes with
CJai approaching to zero have negligible control on it. Therefore, en-
zymes with high CJai in essential metabolic pathways of the parasite are
promising drug targets from a metabolic perspective [22,23,25].
The CJai are systemic properties, i.e. their determination requires a
whole functional pathway, which is achieved only when all involved
players interact with each other. Hence, the CJai cannot be determined
by analyzing or manipulating the enzyme in isolation either in vitro or in
vivo. The CJai can be theoretically predicted by in silico kinetic modeling
of the metabolic pathway. Using this latter strategy, it was previously
predicted that γECS and TryS exert most of the control on the T(SH)2
synthesis flux, with CJai values of 0.58–0.7 and 0.49–0.58, respectively,
and with other steps displaying negative CJai to preserve the summation
theorem [26]. On the other hand, by in vitro reconstitution of the hy-
droperoxide-reducing pathway using the recombinant enzymes, it was
predicted that TXN1 and either TXNPx or GPx are the steps that mostly
control the hydroperoxide reduction flux with CJai values of 0.9 [14]. In
contrast, TryR showed negligible control on both, the T(SH)2 synthesis
[26] and hydroperoxide reduction [14] fluxes.
The present work aims to expand the previous MCA studies and to
authenticate the in silico and in vitro predictions of flux control dis-
tribution of the T(SH)2 metabolism in T. cruzi, by now developing in
vivo experimentation. To this end, the CJai of γECS and TryS on the
T(SH)2 synthesis flux, and TXN1 and TryR on the peroxide reduction
pathway, were determined by modulating the expression of these en-
zymes in the parasites and determining its effects on the pathways’
fluxes. In addition, the previously reported metabolic model of T(SH)2
synthesis [26] was updated and expanded with additionally determined
kinetic data and a new kinetic model of the peroxide reduction pathway
was also constructed. Furthermore, correlations between the degree of
control of the pathway enzymes with Bnz and peroxide resistance, and
infectivity in human cells, were also analyzed. The results indicated
that γECS and TXN1 have high control on their respective pathway
fluxes and are relevantly involved in drug resistance and infectivity.
2. Methods
2.1. Cell culture
The Mexican T. cruzi Queretaro strain (DTUI) [27] was used
throughout the study. Epimastigotes of non-transfected wild type (Wt),
and stable clones created by transfection with empty plasmid (mock)
and plasmids for overexpressing (OE) specific enzymes were grown in
liver infusion-tryptose (LIT) medium {0.5% tryptose - 0.5% liver infu-
sion (DIFCO; Detroit, MI, USA), 0.4% NaCl, 0.04% KCl, 0.42%
Na2HPO4, 0.2% glucose}; supplemented with 10% fetal bovine serum
FBS (Biowest; Nuaillé, France), 25 μg hemin/mL and 100 U penicillin/
mL plus 100 μg streptomycin/mL, and maintained at 28 °C. Where in-
dicated, 300 μg G418/mL (Cayman; Ann Arbor, MI, USA) were added.
To determine their generation time (G), epimastigotes were cultured at
an initial concentration of 0.8× 106 parasites/mL and incubated at
28 °C for 96 h. Each 24 h the number of parasites was determined by
direct counting of motile parasites in a Neubauer chamber or by ab-
sorbance at 600 nm. The G was calculated as the inverse of the growth
rate constant (μ), the latter being the inverse of the slope of a Log2 (OD)
vs. time curve.
2.2. Gene amplification
The TryR and TXN1 genes were ligated into the pTREXn expression
vector specific for T. cruzi [28]. The genes were amplified by PCR using
standard methods with the following nucleotide primers: TryR, sense
5'gcggcggcggcgaagcttatgatgtcaaagatttttg3′, antisense 5′ggcggccgcttaca-
gagatgcttctgaagg3’; TXN1, sense 5'ggcaagcttatgtctggtttggcgaag3′, anti-
sense 5'ggcggccgcttagtcggaccaggggaag3′, both containing HindIII and
NotI restriction sites for oriented ligation. For TryR, a previously re-
ported plasmid containing the gene from the T. cruzi Ninoa strain [26]
was used as template for gene amplification. For TXN1, genomic DNA
from the T. cruzi Ninoa strain was used. The PCR products were ligated
into the pTREXn vector by standard methodologies. Construction of
plasmids for γECS and TryS overexpression has been previously re-
ported [29]. Genes' nucleotide sequences and in-frame plasmid con-
structs were verified by automated Sanger DNA sequencing.
2.3. Parasite transfection
Epimastigotes overexpressing γECS and TryS were created as re-
ported elsewhere [29]; the same protocol was used to obtain clones
overexpressing TryR and TXN1. Briefly, 3× 108 epimastigotes re-
suspended in 350 μL of cold non-supplemented LIT medium were
transfected with 100 μg of cesium chloride-purified plasmid DNA by
electroporation with a BTX ECM 830 electroporator (Harvard Appa-
ratus; Holiston, MA, USA) at 300 V for 70ms in 2mm gap BTX elec-
troporation cuvettes. The parasites were maintained at 4 °C for 5min
and then resuspended in fully supplemented LIT medium and incubated
at 28 °C. After 48 h, 500 μg G418/mL was added to the culture to select
plasmid-containing parasites. After 7 days, an aliquot (500 μL) of the
culture was diluted 10 times in medium lacking the antibiotic and cells
were grown for 5 days; later, they were diluted in medium and exposed
again to antibiotic for 7 days. This procedure was repeated twice to
ensure that most of the parasites were transfectants. The selection
procedure took approximately two months, after which the parasites
were maintained under an antibiotic concentration of 300 μg G418/mL.
As control of the transfection and selection procedure, epimastigotes
were transfected with a pTREXn-GFP construct, treated likewise, and
the total number of transfected parasites was monitored by direct
counting using a fluorescence microscope. Whenever ≈100% of para-
sites were expressing GFP, it was assumed that the parasites transfected
with the other constructs were also completely selected. The selected
parasites grown without drug and grown back with G418, maintained
the resistance and/or fluorescence (GFP control), indicating that the
obtained transfected parasites were stable.
2.4. Cloning of transfected parasites
An heterogeneous population (pop) of stable-transfected parasites,
all selected for antibiotic resistance indicative of harboring an expres-
sion plasmid, was obtained and processed to obtain clones with dif-
ferent levels of enzyme expression by the following protocol. Serial
dilutions (1:2) were performed, starting with 58 parasites in 200 μL of
complete LIT medium with antibiotics and G418 in a 96 well plate and
the cells were grown at 28 °C for at least 4 weeks. From the last dilution
of parasites yielding clones, at least three clones (numbered 1, 2 and 3
as the overexpression level increased) were selected for each over-
expressed protein.
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2.5. Protein content in the overexpressing clones
Soluble cell protein (0.1mg) of selected OE-clones was prepared as
for enzymatic activity (section 2.6). The proteins were separated by
SDS-PAGE. For OE-γECS, OE-TryS and OE-TryR, the separating gel was
prepared at 10% polyacrylamide whereas for OE-TXN1 it was at 20%.
The gels were processed for Coomassie-Blue staining. As we have not
specific antibodies against these enzymes, Western blot analyses were
not performed.
2.6. Enzyme activities in parasites
Control (Wt or mock) and different stable OE-epimastigote clones
were cultured to the late logarithmic phase, harvested by centrifugation
at 4250 x g and washed with PBS. The soluble-enriched fractions were
prepared as described before [29] by lysing the parasites with three
cycles of freezing/thawing and the lysate was centrifuged to collect the
soluble fraction and immediately used for activity determination.
Activities of γECS and TryS in the OE clones and GS in all parasites
were determined as described before [29] by coupling the ADP pro-
duction via pyruvate kinase/lactate dehydrogenase (PyK/LDH) to
NADH oxidation and the change in absorbance was monitored in real
time under initial velocity conditions at 340 nm and 37 °C in a diode
array spectrophotometer (Agilent, Santa Clara, CA, USA). In all assays it
was made sure that the activity was linear with respect to the amount of
soluble cell protein. The 0.5 mL reaction contained 100mM Hepes
buffer pH 7.4, 1mM EDTA, 5mM MgSO4, 100mM KCl, 0.2mM NADH,
2mM ATP, 2mM phosphoenolpyruvate (PEP) and at least 600 mU PyK
and 900 mU LDH. In addition, the following components were added
(the specific thiol substrates were added to start the reactions): for γECS
activity, 0.15–0.25mg soluble cell protein, 1.3 mM Glu and 2.1mM
Cys; for GS activity, 0.005–0.040mg soluble cell protein, 8 mM Gly and
0.4 mM γEC; and for TryS activity, 0.01–0.2 mg soluble cell protein,
11mM Spd and 3mM GSH. To subtract the high spurious ATPase ac-
tivity present in the cell samples (accounting for 150–300 nmol/min x
mg soluble cell protein in the enzymatic assay), a master mix for two
reactions was prepared with all components (including the soluble cell
protein) except the specific thiol substrate; the mixture was divided in
two reactions and only one was supplemented with the corresponding
thiol substrate and changes in the absorbance of the two reactions were
followed in parallel. The activity in the absence of the thiol substrate
accounted for the non-specific activity and was always subtracted. γECS
and TryS basal activities in Wt and mock cells could not be determined
with this protocol since no reliable increased rates above the high
ATPase activity could be distinguished. TryS activity was determined in
soluble cell protein fraction of Wt cells by HPLC. A mixture of reaction
buffer (100mM Hepes pH 7.4, 100mM KCl, 1mM EDTA, 5mM
MgSO4), 2 mM PEP, 2mM ATP, 0.6–0.9 U PyK/LDH and 0.2–0.4 mg of
soluble cell protein was prepared and then divided in three: one was
supplemented with 3mM GSH, the second with 11mM Spd (both were
control reactions) and the third was supplied with both substrates.
Aliquots of 90 μL were transferred to 1.5 mL tubes and incubated at
37 °C for 0, 15, 30 or 60min. After each time, the reaction was stopped
by adding perchloric acid (PCA) at 3% v/v final concentration and
T(SH)2 was determined by HPLC as described in section 2.7 [29].
TryR, TXN1 and TXNPx activities were determined as previously
described [14] by monitoring the T(SH)2-dependent peroxide reduction
associated to NADPH oxidation. For TryR activity the mixture con-
tained 40mM Hepes pH 7.4, 1mM EDTA, 0.16mM NADPH, 0.23mM
TS2 and the cellular sample (5–50 μg soluble cell protein from Wt
clones; and 0.1–0.2 μg soluble cell protein from OE-clones) was added
to start the reaction. For TXN1 and TXNPx, the mixture contained
40mM Hepes pH 7.4, 1mM EDTA, 0.16mM NADPH, 0.45mM (TSH)2,
0.5 μM TryR,> 24 μM TXNPx (for TXN1 determination) or > 22 μM
TXN1 (for TXNPx determination) and 0.1mM cumene hydroperoxide
(CumOOH) was added. The reason to use CumOOH instead of H2O2 is
that the inhibitory effect of the former on TXNPx occurs at a higher
concentration than that of the latter [14], making it feasible to monitor
the steady state of the reaction for a longer period of time. After 3min
baseline stabilization, the reaction was started by adding the soluble
cell protein; when the endogenous enzyme activity levels were de-
termined, the amounts were 0.03–0.4 mg soluble cell protein and
0.03–0.35mg soluble cell protein for TXN1 and TXNPx, respectively;
and 3–30 μg soluble cell protein from the OE-TXN1 clones.
2.7. Metabolite determination
Concentrations of thiol metabolites were determined in the para-
sites as previously described [29]. The cells were grown to the late
exponential phase, harvested and washed twice with PBS. They were
resuspended in lysis buffer (20mM Hepes pH 7.4, 1mM EDTA,
0.15mM KCl) plus 20mM dithiothreitol, disrupted by freezing and
thawing, centrifuged at 17000 x g for 10min and the soluble fraction
was separated. The samples were strongly reduced with NaBH4, acid-
ified with PCA (3% v/v final concentration) and centrifuged at 16,843 x
g for 2min. Twenty microliters of the supernatant were analyzed by
HPLC. The thiol-molecules were post-column derivatized with DTNB
and detected at 412 nm. It was previously demonstrated that non-sig-
nificant T(SH)2 degradation occurs with this protocol [29]. To calculate
the millimolar intracellular concentration, it was here determined that
1×106 epimastigotes have 5 ± 0.8 μg total cell protein (n= 10) and
considered that 1× 109 epimastigotes have an intracellular water vo-
lume of 30 μL [30].
2.8. Supplementation of thiol-molecules and polyamine to epimastigotes
Cultures of epimastigotes (controls and OE-clones) were initiated at
a concentration of 0.8× 106 parasites/mL and incubated at 28 °C for
48 h (reaching a concentration of ≈3×106 parasites/mL), after which
they were separated in 25mL aliquots. One of them was used as a
control (no supplementation) and the other were supplemented with
different concentrations of Cys (0.03, 0.06, 0.1mM; ≈10–33 fmol/
cell), GSH (0.3, 0.6, 1.0mM; ≈100–333 fmol/cell), Spd (0.1 mM; ≈33
fmol/cell) or the combination of Cys plus Spd (0.1mM each; ≈33 fmol/
cell each). The parasites were incubated at 28 °C for further 24 h and
processed for metabolite determination (section 2.7). The difference in
metabolite concentrations before and after 24 h supplementation was
calculated and normalized in percentage versus the control condition
(no supplementation).
2.9. Ex vivo T(SH)2 synthesis flux
Control (Wt and mock) and OE-γECS or OE-TryS epimastigotes were
cultured to the late logarithmic phase and soluble cell protein fractions
were prepared as for enzyme activity determination (section 2.6). The
T(SH)2 synthesis flux was determined ex vivo (using saturating con-
centrations of the precursors Cys, Glu, Gly, ATP and Spd) at room
temperature in 0.5mL of 100mM Hepes pH 7.4, 5mM MgSO4, 100mM
KCl, 1mM EDTA, 2.1mM Cys, 1.3 mM Glu, 8mM Gly, 11mM Spd,
3mM ATP, 2mM PEP, 20mM DTT, at least 600 mU PyK and 900 mU
LDH (the latter two to maintain a high and constant ATP concentration)
and 0.8–1.2mg of soluble cell protein were added to start the reaction.
A control reaction lacking Cys was made in parallel. At 0, 1, 3, 5, 10 and
15min, 90 μL of the reaction were withdrawn and mixed with PCA (3%
final concentration) to stop the reaction. The time-dependent T(SH)2
formation was determined by HPLC as described in the metabolite
determination assay (section 2.7). The T(SH)2 formation rate of the
control reaction lacking Cys was subtracted from the full reaction. For
these experiments it was made sure that the flux was linear with respect
to the amount of protein used.
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2.10. Ex vivo hydroperoxide reduction flux
A soluble cell protein fraction was prepared as for the enzyme ac-
tivities determination assay (section 2.6). The peroxide reduction ex
vivo flux was carried out as previously described [14]. Briefly, the
0.5 mL reaction mixture contained 40mM Hepes pH 7.4, 1mM EDTA,
0.2 mM NADPH, 0.45mM T(SH)2 in-house prepared according to [31]
and 0–2.5mg of soluble cell protein. The reaction was initiated by
adding 0.1 mM CumOOH and the NADPH oxidation was monitored at
340 nm and 37 °C. Also, for these experiments it was ensured that the
flux was linear with respect to the amount of protein used.
2.11. Flux control coefficients
For rigorous determination of flux control coefficients, actual en-
zyme activities are required, regardless of the protein contents. In order
to determine the CJai of the enzymes of the T(SH)2 metabolism, three
clones of the OE-epimastigotes with different levels of enzyme activity
were selected. The effect of changes in enzyme activity on either the ex
vivo T(SH)2 synthesis flux or the ex vivo peroxide reduction flux were
determined. The CJai is determined from the slope of the tangent (i.e., the
derivative) to a curve of pathway flux versus enzyme activity multiplied
by a scalar factor (aio/Jo) that represents the ratio of the values of flux
and enzyme activity at the reference metabolic state (for further details,
see [23–25]). To simplify the procedure due to the high variability in
the biological samples, the percentage of pathway flux versus percen-
tage of enzyme activity compared to control cells (Wt or mock) were
plotted, and the CJai calculated from the derivative at the 100% (control)
activity level in each individual experiment. A requisite for CJai de-
termination is that no significant modifications in the other pathway
enzymes be attained. Therefore, the activities of the other enzymes
from the pathway were also determined on the OE-clones.
2.12. Pathway modeling
Kinetic models for T(SH)2 synthesis and T(SH)2-dependent peroxide
reduction pathways were built using the metabolic simulator software
GEPASI/COPASI [32,33]. The full information for their construction is
included in Supplementary Material 2 (SM2). The models included the
reactions displayed in Fig. S2.1 and Fig. S2.3. A summary of the reac-
tion codification in the software, the kinetic parameters and reaction
kinetic mechanisms [62] are shown in Tables S2.1 and S2.3. The initial
and fixed metabolite concentrations used in the models are provided in
Table S2.2 and Table S2.4. The full kinetic rate equations are described
in SM2. The model files are available on request from the corresponding
author. The characteristics of each model are outlined below.
For the T(SH)2 synthesis, the previously published kinetic model
[26] was improved (Fig. S2.1) by (i) including the kinetic parameters of
the Cys supply reaction (Cys transport; CysT) to simulate the effects of
Cys supplementation on the T(SH)2 pool; the reaction included the Km
value for external Cys previously reported [34], whereas the other re-
quired kinetic and thermodynamic parameters were parameterized to
simulate the internal Cys concentration as experimentally determined.
(ii) including a new TryS rate equation with substrate inhibition by GSH
with kinetic parameters obtained from OE-TryS cell samples and re-
cently reported (Fig. S2 in [29]) with KmGSH=1.6mM and
KiGSH= 7.3mM). (iii) removing GSH and Spd leaks to allow higher
variation of T(SH)2; the reasons for these changes are described in
Results section 3.7. And (iv) replacing TryR and NADPH supply reac-
tions with a reaction of T(SH)2-demand with kinetic parameters of the
peroxide reducing enzymes as previously reported [14] (see further
details in SM2). This kinetic model was also parameterized to simulate
the increase in the thiol pools of parasites supplemented with 0.1mM
Cys.
The kinetic model of the T(SH)2-dependent peroxide reduction
pathway reported here for the first time included the reactions of TryR,
TXN1, TXNPx and NADPH supply (Fig. S2.3). The rate equations were
bi-bi ordered reversible for TryR; ping-pong kinetics for TXN1 and
TXNPx and mass action reversible for NADPH supply (Table S2.3). The
enzyme kinetic parameters Vmax, Km and Ki were those previously
determined by our research group under near-physiological conditions
using the recombinant enzymes [14] (Table S2.3).
The models were refined until they were able to simulate (i) the
steady-state metabolite concentrations as determined within the para-
sites under the different experimental settings used; and (ii) the ex-
perimentally determined fluxes, i.e. the ex vivo pathway flux de-
termined here with parasite cell samples and with the in vitro
reconstituted pathway [14].
2.13. Benznidazole (±BSO) and peroxide resistance assays
Two different protocols were used for Bnz and peroxide resistance
assays. The first protocol included a 24 h exposure, and direct counting
of motile parasites in a Neubauer chamber or the OD600nm determina-
tion. Epimastigotes were cultured at an initial concentration of
0.8×106 parasites/mL and incubated at 28 °C for 48 h, after which the
parasite concentration was determined by direct counting and different
concentrations of Bnz (0.5–11 μM; ≈0.16–3.6 fmol/cell) or Bnz
(2.0–25 μM; ≈0.66–8.3 fmol/cell) plus 0.1mM (≈33 fmol/cell) bu-
thionine sulfoximine (BSO) were added. The parasites were further
incubated at 28 °C and then counted again 24 h later. The difference in
parasite concentrations before and after 24 h drug exposure was con-
sidered as the relative growth, which then was normalized in percen-
tage versus the control condition (no drug added). The concentration at
which the relative growth was decreased by 50% (IC50) was then cal-
culated. For the second protocol, a bolus addition of different H2O2
concentrations (60–250 μM; ≈3.2–13.3 fmol/cell) was used, and the
OD600nm was determined every 24 h over a period of 96 h. The growth
rate constant (μ) was calculated (i.e. the slope of a Log2 (OD) vs. time
curve), and the concentration at which the μ was decreased by 50%
(IC50) was then calculated.
2.14. Parasite host cell infection
Human foreskin fibroblasts (HFF-1) and Rhesus monkey kidney
epithelial cells (LLC-MK2) were grown in culture-treated flasks in
Dulbecco's-MEM with high glucose (GIBCO; MD, USA), supplemented
with 10% FBS (Biowest; Nuaillé, France), 100 U penicillin/mL and
100 μg streptomycin/mL and incubated under 5% CO2 at 37 °C until
70% confluence was reached. The infection protocol was carried out as
previously described [35] with some modifications. Primary infections
of HFF-1 cells cultured in 25 cm2 flasks were initiated with Wt and
newly transfected and selected populations of mock and OE-epimasti-
gotes (2×106 parasites/mL) in Dulbecco's-MEM high glucose supple-
mented with 2% FBS; the interaction of parasites with human cells was
allowed to last for 48 h. Then, the cells were daily washed with serum-
free medium for epimastigote removal and replenished with fresh
medium supplemented with 2% FBS. After 7–8 days post infection
(dpi), trypomastigotes derived from the first burst (0.2× 106 parasites/
mL) were used for a secondary infection of LLC-MK2 cells cultured in 25
cm2 flasks and incubated for 48 h, afterwards the culture was processed
as in the previous step. Trypomastigotes from the first burst were used
to infect HFF-1 cells (tertiary infection)ultured over coverslips in 24
well-plates in quadruplicates; after 2 h incubation the cells were washed
twice to remove non-internalized parasites and replenished with fresh
medium. After 18, 48 or 66 h post-infection, the coverslips were ex-
haustively washed, fixed with 4% formaldehyde, stained with DAPI by
standard methods and the number of infected cells as well as the
number of internal parasites was analyzed by fluorescence microscopy.
At least 500 cells per coverslip were analyzed.
To examine the trypomastigotes bursting, HFF-1 cells were grown in
24 well-plates (in the absence of coverslip) and infected as above. The
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trypomastigotes in the supernatants were resuspended and collected at
the fourth and fifth day to determine by direct counting in the
Neubauer chamber the number of trypomastigotes that had burst into
the extracellular medium.
3. Results
3.1. Cell growth in stable transfectants
The generation time (G) in at least three independent cultures of the
different OE-TryS (23.6 ± 2.5 h), OE-TryR (23.4 ± 3.1 h) and OE-
TXN1 (25.6 ± 4.1 h) clones was similar in comparison to that of Wt or
clones of mock cells (24 ± 2.7 h and 24.3 ± 2.1 h, respectively), ex-
cept for OE-γECS, whose value (26.3 ± 3.7 h) was higher (p < 0.05),
thus growing slower than Wt and mock cells. In addition, the genera-
tion time of mock cells in the absence or presence of G418 showed no
difference vs. control cells (23.9 ± 1.4 h). The G values were similar
whether optical density or direct cell counting methods were used.
3.2. Protein contents and enzyme activities in control and enzyme-
overexpressing parasites
SDS-PAGE analysis of the soluble cell protein fractions from Wt,
mock and OE-parasites showed that the targeted proteins in the OE-
TryS, OE-TryR and OE-TXN1 clones were indeed overexpressed (Fig.
S1.1 in supplementary material 1; SM1). However, no clear over-
expression of γECS was apparent in the cell samples.
The basal γECS activity in the absence of overexpression cannot be
accurately determined due to a high spurious ATPase activity in the
assay (150–300 nmol/min x mg soluble cell protein). By performing the
appropriate control reactions as described in the methods section and
subtracting the unspecific ATPase reaction, it was established that a
reliable difference for the specific activity should be at least 3 nmol/min
x mg soluble cell protein above the unspecific rates; hence the basal
γECS activity was below this threshold value. Despite this high ATPase
activity, γECS and TryS were reliably determined above the threshold in
their respective OE-clones using the PyK/LDH coupled assay.
An effort was made to determine TryS activity in Wt cells by de-
termining the T(SH)2 production through HPLC as described in
methods. A typical HPLC profile (Fig. S1.2 in SM1) shows a time-de-
pendent increase in T(SH)2 using 3mM GSH. A value of 0.63 ± 0.19
nmol/min x mg cell protein for TryS activity was determined in 5 in-
dependent parasite cultures. This value does not correspond to the ac-
tual Vmax, since TryS shows substrate inhibition by GSH. To circum-
vent this problem, it was determined from GSH saturation curves of
TryS activity in OE-TryS clones and by fitting of the experimental data,
that the TryS Vmax was underestimated by nearly 50% (Table S1.1 in
SM1). Therefore, it was assumed that in Wt epimastigotes the TryS
Vmax was ≈1.2 ± 0.4 nmol/min x mg cell protein.
The levels of increased activity were on average≈8 for OE-γECS,
≈75 for OE-TryS, ≈31 for OE-TryR and ≈13 for OE-TXN1 (Table 1).
This indicated that the parasite clones indeed functionally over-
expressed their respective enzymes. These overexpression levels did not
significantly vary among clones of the same OE-parasites, except in
some cases (Table 1). Unless overexpressed, the basal activities of TryR,
TXN1 and TXNPx were unaltered in the OE-clones, whereas a decreased
GS activity was determined in several clones. OE-clones randomly
evaluated showed that their activities did not depend on the G418
concentration used (300 or 500 μg G418/mL) or its absence for about 2
months (data not shown). Nevertheless, the parasites were always
grown in the presence of G418 to prevent unexpected changes in the
enzyme activities.
3.3. Metabolite pools in transfected cells
Mock and Wt cells showed similar thiol-molecule contents (Fig. 2A).
OE-γECS3 cells showed 3.5-fold increased T(SH)2 concentration in
comparison to mock cells (Fig. 2A). Analysis of the thiol contents in
different OE-γECS clones revealed that when the γECS activity
reached>10 nmol/min x mg soluble cell protein (clone C in Fig. 2B
and Table S1.2 in SM1), the T(SH)2 concentration became clearly
higher than in mock cells, reaching up to 4-fold more when the activity
was 22 nmol/min x mg soluble cell protein. Moreover, the T(SH)2 level
increased by≈6-fold when OE-γECS cells were supplied with 0.1 mM
Cys or 1mM GSH, which was ≈2-fold above the increases attained in
similarly supplemented mock cells (Fig. S1.3 in SM1). Higher con-
centrations of added Cys (0.2–1mM) or GSH (up to 5mM) resulted in
lower T(SH)2 increases of 4.5- and 3.5-fold and even some inhibition
(data not shown). On the other hand, OE-TryS1 cells showed similar
T(SH)2 levels as Wt and mock cells, either supplemented with Cys, GSH
or Spd or non-supplemented. This unexpected result is examined in the
next section.
Table 1
Activities of the T(SH)2 metabolism enzymes in T. cruzi epimastigotes overexpressing different enzymes.
Specific activity (nmol/min x mg soluble cell protein)
γECS OE/Mock GS OE/Mock TryS OE/Mock TryR OE/Mock TXN OE/Mock TXNPx OE/Mock
Wt < 3& 1 23 ± 10 0.8 ± 0.3 1.2 ± 0.4§ 1 334 ± 111 1.1 ± 0.4 33 ± 11 1.0 ± 0.3 66 ± 25 0.9 ± 0.3
Mock < 3& 1 28 ± 7 1 1.2$ 1 291 ± 100 1 32 ± 11 1 73 ± 20 1
γECS 1 12 ± 2* 4 ± 1* 23 ± 13 0.8 ± 0.5 ND ND 341 ± 54 1.2 ± 0.2 30 ± 12 0.9 ± 0.4 85 ± 15 1.2 ± 0.2
γECS 2 16 ± 7*ℵ 5 ± 2* 15 ± 6* 0.5 ± 0.2* ND ND 368 ± 63 1.3 ± 0.2 57 ± 33 1.8 ± 1.0 86 ± 16 1.2 ± 0.2
γECS 3 22 ± 3*ℵ 7 ± 1* 18 ± 8 0.6 ± 0.3 ND ND 321 ± 49 1.1 ± 0.2 27 ± 13 0.9 ± 0.4 88 ± 7 1.2 ± 0.1
TryS 1 ND ND 14 ± 6* 0.5 ± 0.2* 77 ± 24* 64 ± 20* 347 ± 120 1.2 ± 0.4 29 ± 8 0.9 ± 0.3 97 ± 37 1.3 ± 0.5
TryS 2 ND ND 11 ± 4* 0.4 ± 0.2* 95 ± 17* 79 ± 14* 283 ± 60 1.0 ± 0.2 27 ± 12 0.8 ± 0.4 67 ± 27 0.9 ± 0.4
TryS 3 ND ND 11 ± 4* 0.4 ± 0.1* 98 ± 45* 81 ± 37* 346 ± 160 1.2 ± 0.6 49 ± 26 1.5 ± 0.8 86 ± 30 1.2 ± 0.4
TryR 1 ND ND 20 ± 10 0.7 ± 0.3 ND ND 6.1 ± 3.4
(x103)*#
21 ± 12*# 34 ± 13 1.1 ± 0.4 68 ± 16 0.9 ± 0.2
TryR 2 ND ND 21 ± 4 0.7 ± 0.5 ND ND 6.8 ± 2.5
(x103)*#
23 ± 8.5*# 34 ± 11 1.1 ± 0.3 77 ± 27 1.1 ± 0.4
TryR 3 ND ND 14 ± 3* 0.5 ± 0.1* ND ND 14.4 ± 7.7
(x103)*
50 ± 27* 32 ± 12 1.0 ± 0.4 64 ± 12 0.9 ± 0.2
TXN1-1 ND ND 8 ± 3* 0.3 ± 0.1* ND ND 293 ± 71 1.0 ± 0.2 379 ± 175* 12 ± 5* 73 ± 23 1.0 ± 0.3
TXN1-2 ND ND 9 ± 5* 0.3 ± 0.2* ND ND 317 ± 69 1.1 ± 0.2 399 ± 164* 12 ± 5* 79 ± 19 1.1 ± 0.3
TXN1-3 ND ND 11 ± 6** 0.4 ± 0.2** ND ND 318 ± 51 1.1 ± 0.2 490 ± 230* 15 ± 7* 83 ± 22 1.1 ± 0.3
& threshold reliable specific enzymatic activity after the spurious ATPase activity was subtracted. ND: below the threshold confidence activity of the PyK/LDH
coupled assay. § value determined by HPLC. $ value assumed to be similar to that of Wt. Values are the mean ± SD of at least three independent cultures. Student's t-
test for non-paired samples *p < 0.01, **p < 0.05 vs. mock. ℵp< 0.01 vs. γECS 1, #p < 0.05 vs. TryR3.
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The OE-TXN1-2 cells consistently showed increased Cys and GSH
concentrations (≈75% and 60%, respectively) above control cell levels,
but they showed no changes in T(SH)2 levels (Fig. 2A). OE-TryR3 cells
showed a slight increase in thiol contents (≈30–40%) compared to
control cells, although it was not statistically significant (Fig. 2A).
3.4. TryS overexpression did not induce increased T(SH)2 levels
Unexpectedly, OE-TryS1 cells showed non-significant changes in
T(SH)2 vs. mock cells (Fig. 2A), despite the at least 64-fold increase in
enzyme activity (Table 1). This has also been observed by others [36],
where TryS overexpressing epimastigotes (but not trypomastigotes) did
not increase their T(SH)2 pool. To further examine this counterintuitive
result, the OE-TryS1 cells were grown with supplementation of (i) Cys,
to circumvent a possible Cys deficit for endogenous γECS activity and
hence low GSH synthesis; (ii) GSH, to directly increase the TryS sub-
strate; and (iii) Spd, to determine whether this precursor was limiting.
OE-TryS1 cells supplemented with 1mM GSH showed a similar increase
in T(SH)2 to that observed in control cells, and lower levels when
supplemented with 0.1 mM Cys (Fig. S1.3). On the other hand, Spd
seemed not to be limiting for T(SH)2 synthesis because (i) their basal
concentration in Wt cells is high 0.8 ± 0.2mM [29]; (ii) there should
be no increase in T(SH)2 in the OE-γECS cells by merely supplementing
with Cys or GSH (Fig. S1.3); and (iii) the OE-TryS1 parasites supple-
mented with Spd alone did not increase their T(SH)2 (Fig. S1.4 in SM1).
Furthermore, in experiments to determine the ex vivo T(SH)2
synthesis flux in OE-TryS clones, no net increase in T(SH)2 was attained,
despite the presence of saturating Cys, Glu, Gly, ATP and Spd con-
centrations (see Methods section for details). Instead, a time-dependent
increase in GSH was observed in the cell protein samples of OE-TryS
cells, which was not evident in the ex vivo flux determinations in Wt,
mock and OE-γECS cell samples. Such pattern in the OE-TryS clones
suggested that (i) T(SH)2 might be simultaneously synthesized and
degraded at similar rates or (ii) overexpressed TryS was not active. The
latter possibility can be ruled out, because high TryS activities were
indeed determined in the OE-TryS parasites (Table 1), although it is
unknown whether in intact cells any type of negative metabolic reg-
ulation may occur.
To analyze the possibility of T(SH)2 degradation in the OE-TryS
cells, soluble cell protein fractions from the OE-TryS1 clone were in-
cubated in the absence or presence of 1mM T(SH)2. Time-dependent
increases in GSH (40–80 nmol/min x mg soluble cell protein) and de-
creases in T(SH)2 (10–30 nmol/min x mg soluble cell protein) were
observed (Fig. S1.5 in SM1), indicating T(SH)2 degradation. The cal-
culated rates of T(SH)2 degradation in the OE-TryS cell samples were
13 ± 5 and 21 ± 9 nmol/min x mg soluble cell protein in the absence
or presence of added T(SH)2, respectively. In contrast, cell soluble
protein fractions from Wt and mock cells did not show significant
T(SH)2 degradation (Fig. S1.5 in SM1). These observations may explain
the lack of net increase in T(SH)2 in the OE-TryS1 epimastigotes in
comparison to control cells (Fig. 2A).
3.5. Trypanothione synthesis and peroxide reduction ex vivo fluxes
T(SH)2 is not a metabolic pathway end-product (such as lactate or
ethanol for glycolysis or CO2 for the Krebs cycle) since there are still
enzymes or processes using it. Hence, at a specific metabolic steady
state, the T(SH)2 moiety pool in the cell is the result of the dynamic
balance between its synthesis (i.e. supply) and consumption (i.e. de-
mand). For these reasons, determination of fluxes of the T(SH)2 meta-
bolism in intact parasites would require more sophisticated techniques
such as labeling studies or fluxomics. To circumvent this limitation, the
fluxes were determined ex vivo, in parasite soluble cell protein fractions.
However, it has to be considered that (i) the values determined re-
present the maximal fluxes of synthesis with the enzymes expressed in
the cell sample, because the pathway precursors Cys, Glu, Gly, Spd and
ATP are saturating and thus the limiting factor should only be the
content of active enzymes in the cell sample; and (ii) in the ex vivo
system most likely some physiological regulatory interactions are lost.
The T(SH)2 synthesis flux was linear for up to 5min using
0.3–0.8mg soluble cell protein when Wt or OE-γECS3 soluble cell
protein fractions were used (data not shown). If the specific pathway
substrate Cys was not added to the reaction, the basal T(SH)2 content
did not change over time, indicating that it was not significantly syn-
thesized or degraded. Under such conditions, the maximal ex vivo
T(SH)2 synthesis flux in Wt cells was 0.6 ± 0.2 nmol T(SH)2/min x mg
soluble cell protein (n=5) (Table 2), whereas in the OE-γECS3 clone
with the highest activity (20 nmol/min x mg soluble cell protein) the
flux was 2 ± 0.4 nmol T(SH)2/min x mg soluble cell protein (Table
S1.2 in SM1). Since in the OE-γECS3 cells γECS activity was in excess in
comparison to GS and TryS activities, these results also suggested that
(i) the basal TryS activity should not exceed 2 nmol/min x mg soluble
cell protein, i.e. the maximal T(SH)2 synthesis flux in OE-γECS3 cells;
such a value is in the range of the TryS activity calculated from the
HPLC results; and (ii) the basal γECS activity should not exceed
1.2 nmol/min x mg soluble cell protein, i.e. the pathway flux in the Wt
cells multiplied by two (considering the pathway stoichiometry). In
contrast, for the OE-TryS1 cells, which have a TryS activity of 77 nmol/
min x mg soluble cell protein, a maximal flux output of only 0.3 nmol
T(SH)2/min x mg soluble cell protein was obtained, which was even
lower than in Wt cells.
For the peroxide reduction flux, the maximal flux outputs in the Wt
and mock cells were 11 ± 5 and 11 ± 4 nmol/min x mg soluble cell
protein, respectively, values that were not significantly different in the
OE-TryR3 cells (14 ± 4 nmol/min x mg), which showed the highest
level of TryR overexpression. In contrast, in the OE-TXN1-3 with the
Fig. 2. Thiol contents in control and overexpressing para-
sites. (A) Thiol metabolites in parasites correspond to: Wt
(wild type); mock (cells transformed with empty plasmid);
γECS3 (OE-γECS clone 3); TryS1 (OE-TryS clone 1); TryR3
(OE-TryR clone 3), TXN1-2 (OE-TXN1 clone 2). 100% levels
in mock cells corresponded to: Cys, 6.6 ± 2.2 nmol/mg
cell protein (1.2 ± 0.4mM); GSH, 9.4 ± 3.5 nmol/mg cell
protein (1.1 ± 0.4mM); T(SH)2, 4.7 ± 1.8 nmol/mg cell
protein (0.9 ± 0.3mM). At least 28–45 different in-
dependent cell cultures for Wt and mock cells and at least
12–35 independent cultures for the OE-clones were used.
t (B) Thiol metabolite concentrations in different γECS
overexpressing clones. γECS activities for clones 1–3 are
shown in Table 1; the values for clones A-D are shown in
Table S1.2 in Supplementary Material 1.100% thiol con-
centration in mock cells correspond to: Cys=6.8 ± 0.8 nmol/mg cell protein (1.1 ± 0.1mM); GSH=9.8 ± 3.8 nmol/mg cell protein (1.6 ± 0.6mM);
T(SH)2=4.5 ± 1.7 nmol/mg cell protein (0.7 ± 0.3mM). Student's t-test for non-paired samples *p < 0.05, **p < 0.01 vs. mock.
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highest TXN1 activity, the flux reached a value of 46 nmol/min x mg
soluble cell protein. This latter observation suggests that the basal
TXN1 levels are limiting for the peroxide reduction flux.
3.6. Flux control distribution of the T(SH)2 synthesis and peroxide
reduction pathway from parasites
To determine the CJai of the pathway enzymes, the dependence of the
pathway flux on the enzyme activities has to be analyzed. It is necessary
to emphasize that the actual enzyme activity in the cell is required for
CJai determination; the protein contents (e.g. determined by Western
blotting) may provide inaccurate values since a considerable protein
fraction may have low or no activity. This was the reason why in the
present study the enzyme activities within the parasites were rigorously
established. The levels of enzymes were specifically varied in the OE
clones without substantial changes in other pathway enzymes (Table 1),
which is another mandatory requisite for appropriate CJai determination.
The enzyme variability shown among the different biological replicas of
each cell clone allowed obtaining clustered points along the curve of
pathway flux versus enzyme activity using only three clones per enzyme.
Fig. 3A shows the variations in the ex vivo T(SH)2 synthesis flux
when the activity of γECS was varied using the different parasite clones.
A CJai of 0.69 ± 0.15 (Table 2) was obtained for γECS at the Wt level of
activity (taken to be 3 nmol/min x mg soluble cell protein, the threshold
confidence value of the enzymatic assay). Unfortunately, the CJai for
TryS could not be determined because of lack of variation of the T(SH)2
content in the parasites as described above. Notwithstanding this in-
convenience for this ex vivo analysis, it was estimated that TryS may
have a CJai of at most 0.31, by using the MCA summation theorem and
assuming negligible control exerted by GS [26], the latter based on its
higher activity in the parasites with respect to γECS and TryS (Table 1).
On the other hand, the peroxide reduction flux showed non-sig-
nificant variations when TryR activity was increased up to ≈50-fold
above Wt level (Fig. 3B); the calculated CJai for TryR was 0.15 ± 0.09
(n= 8). In contrast, when TXN1 was varied (Fig. 3C), the flux changed
almost linearly near the Wt level, with a concomitant CJai of
0.73 ± 0.29 (n= 7). As TXNPx was not overexpressed in the parasites,
the ex vivo CJai could not be obtained in a similar fashion to that for TryR
and TXN1. In an attempt to determine the CJai of TXNPx, the peroxide
reduction flux of soluble cell protein fractions from Wt and mock cells
was titrated by adding recombinant TXNPx (Fig. S1.6 in SM1). The data
showed that the flux increased while increasing TXNPx activity in a
similar fashion to that of TXN1, yielding a CJai near 0.57–0.64 for
TXNPx; hence, the control of the flux is shared equally by both TXN1
and TXNPx.
3.7. Flux control distribution of T(SH)2 synthesis by pathway modeling
An updated kinetic model of T(SH)2 synthesis was constructed based
upon a previous version published by our group [26]. In the previous
version of the model the predicted CJai of TryS (0.46–0.58) was higher
than that obtained ex vivo here using parasite samples. In addition, the
predicted CJai of SpdT (0.22–0.24) was also high in the previous model;
however, the Spd supplementation experiments in parasites showed no
increases in T(SH)2 (Fig. S1.4 in SM1), suggesting lower control than
previously predicted for the polyamine supply. Simulations for the
Table 2
Experimental and kinetic modeling results for the T(SH)2 synthesis pathway.
40 μM external Cys 140 μM external Cys
In vivo/ex vivo Model In vivo Model
Metabolite (mM)
Cysin 1 ± 0.2 0.5 1.8 ± 0.7 1.78
GSH 1.4 ± 0.4 1.36 2.7 ± 0.9 2.6
T(SH)2 0.9 ± 0.4 0.75 2.6 ± 0.9 3.5
Spd int 0.78 ± 0.2 1.06 1.05 ± 0.3 0.99
TS2 ND 0.06 ND 0.16
Flux
JTryS 0.6 ± 0.2 (max)* 0.12 ND 0.31
CJai
CJCysT 0.13** 0.09 0.02
CJγECS 0.69 ± 0.15
0.87 (γECS-TryS)**
0.74 0.6
CJGS 8 e−6 5 e−6
CJTryS 0.15 0.26
CJSpdT 0.003 0.015
CJTSH dem 0.003 0.06
CJTSH leak 0.012 0.05
Flux in nmol/min x mg cell soluble protein. * Maximal ex vivo T(SH)2 synthesis.
** Values obtained by elasticity analysis. ND not determined. Cysin means in-
ternal Cys.
Fig. 3. Determination of flux control coefficients.
Variations in activity were achieved from clones de-
scribed in Table 1. At least 5 independent titrations (in-
dicated with different symbols) were made with three
different clones. 100% pathway fluxes were: (A) T(SH)2
synthesis, 0.6 ± 0.2 nmol T(SH)2/min x mg soluble cell
protein; (B) and (C) CumOOH reduction, 11 ± 4 nmol/
min x mg cell soluble protein. The solid lines represent
the global fitting of all data points by the Michaelis-
Menten equation (without a mechanistic meaning). The
vertical line shows the point at which the CJai was calcu-
lated and corresponds to the basal activity level in Wt
(panel A) or mock (panels B and C) cells. Due to experi-
mental variations between Wt and mock cells in the hy-
droperoxide reduction flux determination assays, some
points showed values above 100% of flux (corresponding
to Wt).
Z. González-Chávez, et al. Redox Biology 26 (2019) 101231
8
present study using the published model indicated that the high control
values predicted for TryS and SpdT were due to the inclusion of GSH
and Spd leak reactions. These two leak reactions decrease substrate
availability to TryS, decreasing its rate, with the concomitant higher
predicted CJai value for TryS. The GSH and Spd leaks also increased the
CJai predicted for γECS, resulting in the sum of the CJai of γECS and TryS
being higher than one, which was compensated by the negative CJai of
the GSH and Spd leaks. For all these reasons the latter reactions were
removed. In contrast, the supplementation experiments with Cys (Fig.
S1.3 in SM1) indicated that the basal Cys level was limiting for the γECS
activity and therefore, an extracellular Cys uptake (CysT reaction) was
now included, for which some reported kinetic parameters are avail-
able. However, it should be noted that CysT may actually represent any
other reaction or metabolic pathways providing Cys to the cell.
A refined model was here obtained, which was able to closely re-
produce the metabolite concentrations found experimentally in the
parasites without Cys supplementation (Cys concentration in the
medium was 0.04mM), although the simulated flux was lower than
that obtained ex vivo (Table 2). The CJai of 0.74 for γECS in the model
simulation (Table 2) agreed with that obtained ex vivo of CJai=0.69
(Fig. 3A). The model predicted a CJai of 0.15 for TryS, a lower value than
that previously reported, but this enzyme was still the second most flux-
controlling enzyme in the T(SH)2 synthesis pathway. The CysT CJai of
0.09 was low whereas GS showed negligible control.
To further demonstrate the degree of control of Cys supply in vivo,
elasticity analysis [23–25,37] was performed (Fig. S2.2 in SM2) using
data of the Cys, GSH and T(SH)2 thiol changes after Cys supplementa-
tion and BSO inhibition experiments previously published (Figs. 3A and
2 left panel, respectively in [29]). In elasticity analysis, intact cells are
used and no modification of the enzymes is required, but manipulation
of the intracellular steady-state levels of the pathway intermediates is
performed by varying the pathway's initial substrate and by inhibiting
the downstream pathway steps (see reference [23] for further details on
elasticity analysis). The elasticity coefficients toward internal Cys for
the Cys-supply reactions (in this case CysT) and for the Cys-consuming
group of reactions (γECS, GS and TryS) were determined. Their re-
spective CJai were determined by applying the summation and con-
nectivity theorems of MCA [23–25]. CJai values of 0.13 for CysT and
0.87 for the Cys-consuming group of reactions were obtained (Table 2),
which are in agreement with the sum of the CJai of γECS, GS and TryS
obtained by modeling.
Afterwards, it was tested whether the model was able to simulate
the increases in thiol intermediates found in parasites supplied with
0.1 mM Cys; however, merely increasing the Cys concentration did not
predict the in vivo metabolite contents. The model required to si-
multaneously increase the Vmax values of CysT, γECS and TryS (para-
meterized in the model; Table S2.1 in SM2) to become able to simulate
the metabolite concentrations found in Cys supplied parasites (Table 2).
With these latter modifications, the pathway flux increased by 2.6-fold,
which was still within the value experimentally determined, and the
model predicted a high control by γECS, an increased CJai for TryS of
0.26 and again negligible control exerted by GS. Thus, the TryS control
was lower than that of γECS, but higher than that of the Cys supply.
3.8. Flux control distribution of the peroxide reduction flux by pathway
modeling
The kinetic model for the T(SH)2-dependent peroxide reduction flux
considered TXN1 as an enzyme with ping-pong kinetics using the ki-
netic parameters previously determined [14]. The model closely si-
mulated the pathway flux determined ex vivo using soluble cell protein
fractions from Wt and mock cells (Table 3), as well as the flux attained
in the in vitro pathway reconstitution with the recombinant enzymes
previously reported [14]. Likewise, the model simulated with high ac-
curacy the CJai determined here ex vivo by TXN1 and TryR titrations in
the parasite and predicted a CJai for TXNPx of 0.17–0.2.
On the other hand, it has been proposed that kinetics of redoxins,
such as TXN1, should be described using a mass-action equation, since
Michaelis-Menten kinetics appears to be an inaccurate descriptor of
redoxin activities [38]. Thus, the model was modified with the mass
action reversible equation for TXN1, which required parameterization
of the mass action k values of TXN1 and NADPH supply reactions
(described in SM2). With this modification, the model closely predicted
pathway flux (6.4 nmol/min x mg cell protein) and CJai values for TXN1
(0.74) and TXNPx (0.2), as well as for TryR (CJai=0.001) and NADPH
supply (CJai=0.06).
3.9. Resistance to Bnz and peroxides
γECS overexpression led to increased T(SH)2 synthesis and T(SH)2
pool, whereas TXN1 overexpression led to an increase in the peroxide
reduction flux. To determine whether these changes in the parasite anti-
oxidant metabolism could affect other cellular functions, Wt, mock, and
OE-clones were exposed to the antichagasic drug Bnz, alone or in
combination with BSO. Statistically non-significant differences in the
IC50 on growth were observed between mock and the OE-clones using
Bnz alone, except for OE-TryR which was more sensitive (Fig. 4A,
Table 4). For comparative purposes, the IC50 of Wt epimastigotes was
determined, which was higher than that for mock cells (Table 4). A
possible explanation for the difference in their IC50 values is that mock
cells (and OE-clones) were simultaneously exposed to G418 and Bnz,
whereas Wt cells were not treated with the antibiotic.
The susceptibility of the cells to Bnz was increased by exposing them
to a combination of this drug with 0.1 mM BSO (Fig. 4B). It was pre-
viously demonstrated that BSO not only inhibits γECS, but also TryS
[29]. The reported IC50 value on growth for BSO alone in Wt and OE-
clones is > 3.3mM [29]; hence, BSO at a concentration of 0.1 mM is
expected to have no effect on parasite growth; nonetheless, BSO could
potentiate the Bnz effect. In the Bnz + BSO combination, only OE-
TXN1 showed a significant increased resistance, compared to mock
parasites (Fig. 4B and Table 4).
Next, the parasites were exposed to H2O2. OE-TryR3 and OE-TXN1-
2 clones were more resistant than the other clones analyzed (Fig. 4C,
Table 4) with IC50 values higher than 250 μM.
Table 3
Ex vivo, in vitro and kinetic modeling results for the T(SH)2-dependent peroxide
reduction pathway.
Ex vivob In vitro pathway
reconstitution c
Predictions of the
kinetic modeld
CumOOH mM 0.1 0.1** 0.1 fixed
[T(SH)2] mM 0.45 0.45** 0.465
[TS2] mM ND 0.00058
NADPH mM 0.16 0.16** 0.16
NADP+ mM ND 0.025
[TXNox] μM 0.022–0.078* 0.1** 0.083–0.089
[TXNred] μM 0.021–0.027
JTXNPx a 11 ± 5 4.9 ± 2.4 6.1–7.8
CJTryR 0.15 ± 0.09 0.2 ± 0.04 0.11–0.16
CJ TXN1 0.73 ± 0.29 1 ± 0.1 0.64–0.73
CJTXNPx ND 1 ± 0.1 0.17–0.2
CJ NADPH supply ND ND 3.3–6.5 e −5
*interval calculated amount of total TXN1 in 1 mg soluble cell protein using the
formula Vmax= kcat x [total enzyme] where Vmax was that of Table 1 and kcat
was 1560 min−1.
**Initial metabolite and TXN1 concentrations used in the in vitro reconstituted
pathway with the recombinant enzymes. ND Not determined.
a Flux of CumOOH reduction through TXNPx in nmol/min x mg soluble cell
protein.
b The present study.
c Data from [14].
d Model predictions obtained with different KmTXN1 in the TXN1 reaction as
discussed in Table S2.3 in SM2.
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3.10. HFF-1 cell infection
In order to investigate if these antioxidant enzymes are involved in
the infection process of T. cruzi, the infectivity of OE parasites was
assessed. It is known that epimastigotes have to differentiate to trypo-
mastigotes in order to acquire the capability of invading host cells.
Therefore, differences in infectivity using a primary infection with
epimastigotes may be due to differences in differentiation, leading to
misinterpretation. Thus, to discard any epimastigotes engagement,
trypomastigotes derived from secondary infection were used to assess
infectivity in tertiary infections of non-phagocytic cells, since these cells
are major targets for T. cruzi infection in vivo. After 2 h of parasite and
HFF-1 cells interaction, the invasion capabilities of the trypomastigotes
was analyzed at 18 h post-infection (hpi) by determining the number of
infected cells. The results showed that Wt and mock parasites have si-
milar infection rates, in contrast OE-γECS trypomastigotes displayed a
significantly (p < 0.01) higher infection rate of 30%. TryS trypomas-
tigotes (32%, p < 0.05) and TryR trypomastigotes (34%, p < 0.05)
only showed a tendency to a higher infection rates in comparison to
controls (Fig. 5A).
Afterwards, the evolution of the infection was analyzed by de-
termining the number of intracellular amastigotes as an indicative of
transformation from trypomastigote into amastigote inside the cell (at
18 hpi) and amastigotes proliferation (at 48 and 66 hpi). There were no
differences among controls and OE-parasites, showing that they were
able to transform and replicate to the same extent (Fig. 5B).
Finally, to determine whether the overexpression of any enzyme
confers an advantage in parasite burst, released trypomastigotes at 4
and 5 dpi were determined (Fig. 5C). Remarkably, OE-TXN parasites
showed a 3-fold increase in trypomastigotes burst vs other OE- and
control parasites.
4. Discussion
In the studies reported so far about T(SH)2 metabolism in T. cruzi,
the pathway enzymes have been mostly individually analyzed, focusing
on studying the effects of its manipulation on some metabolic or phy-
siological functions, or characterizing the resulting phenotypes (for
instance [19,36,39,40]). Therefore, the aim of the present work was to
perform integral analyses of the complete pathway by modulating
several enzyme activities in the parasites and performing parallel de-
terminations of enzyme activities, metabolite concentrations and
pathway fluxes. This approach allowed to identify which enzymes, and
why, have most of the control on the T(SH)2 synthesis and on the
peroxide reduction pathways, and to establish whether their degree of
control correlate with essential physiological functions such as peroxide
management, antichagasic drug resistance, and infectivity.
4.1. In silico and ex vivo flux control coefficients of the T(SH)2 synthesis
pathway
The updated T(SH)2 synthesis model reported here predicted CJai
values of 0.74 for γECS, 0.15 for TryS and 0.09 for CysT under control
non-Cys supplied conditions. The ex vivo and in silico high CJai de-
termined for γECS correlated with the significant increase in the T(SH)2
and GSH pools developed in the absence and presence of external Cys
supplementation. Although the flux-control distribution was not de-
termined in vivo in parasites supplied with Cys, the model predicted a
decrease in the CJai of γECS and CysT and a gain in TryS control, the
latter attaining CJai values of 0.15–0.31. These results indicated that
γECS retained the main (but not exclusive) control of the T(SH)2
synthesis flux, sharing control with TryS. Under all conditions analyzed,
GS exhibited negligible control on the T(SH)2 synthesis.
Fig. 4. Benznidazole and H2O2 resistance.
Percentage of relative growth of control and OE-
epimastigotes after exposure for 24 h to different
Bnz concentrations and in the absence (A) or
presence of 0.1mM BSO (B). (C) Percentage of
rate growth monitored each 24 h for 96 h in
control and OE-epimastigotes in the presence of
different concentrations of H2O2. Data are
mean ± SD for at least 4 independent cultures.
Concentrations expressed as fmol/cell can be
found in section 2.13.
Table 4
IC50 on growth of T. cruzi epimastigotes for Bnz, Bnz plus BSO, and H2O2.
Cellsa IC50 (μM)
Bnz Bnz + 0.1 mM BSO H2O2
Wt 12 ± 2 5 ± 1** 145 ± 36
Mock 9 ± 3 3 ± 1 135 ± 50
OE- γECS3 11 ± 3 4 ± 1 172 ± 48
OE-TryS1 11 ± 5 5 ± 2 163 (2)
OE-TXN1-2 12 ± 6 6 ± 1** >250 (4)
OE-TryR3 5 ± 1* 3 ± 1 >250 (4)
*p < 0.05 **p < 0.01 vs. mock cells.
a Mock and OE-parasites were grown in the presence of the G418 antibiotic,
in addition to the other indicated compounds. Values are mean ± SD of at least
three independent parasite cultures, except when indicated with the number in
parentheses. Student's -t- test for non-paired samples.
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The high control attained by γECS may be explained by its very
likely low activity in the parasites (< 2 nmol/min x mg soluble cell
protein), the latter value predicted from the ex vivo T(SH)2 synthesis
fluxes using the OE-clones (section 3.5) and by pathway modeling
(section 3.7). Determination of basal γECS and TryS activities in try-
panosomatids is not a trivial task; the high spurious endogenous ATPase
activity makes it cumbersome to discern specificity using enzymatic
coupled assays. However, we were able to determine TryS activity in Wt
epimastigotes by HPLC and using appropriate control reactions; the
value was remarkably similar to that initially predicted by pathway
modeling. Recently, a TryS basal activity in T. cruzi epimastigotes
(Silvio strain) of ≈8 nmol ATP transformed to ADP/min x mg cell
protein as determined by an end-point colorimetric assay of Pi release
was reported [36]. Unfortunately, inclusion of control enzymatic re-
actions, such as whether the ATPase activity was subtracted or whether
the assay was conducted under conditions of initial velocity regarding
protein sample, substrate saturation and time were not described;
therefore, such basal TryS activity value in the parasites may have been
overestimated. To our knowledge, our study represents the first sig-
nificant effort in determining the activities of the T(SH)2 synthesis en-
zymes within trypanosomatids. Unfortunately, γECS activity could not
be determined by HPLC due to overlapping of γEC and GSH peaks.
On the other hand, OE-TryS epimastigotes did not increase the
T(SH)2 content above the wild type level under any condition. A similar
observation was found in [36] when TryS was also overexpressed in
epimastigotes of the Silvio strain. In the latter study, the authors pro-
posed that polyamine uptake exerted a higher metabolic control of the
pathway; however, this seemed unlikely, because Spd supplementation
in our OE-TryS clones did not bring about a further increase in T(SH)2.
Since in the present study a high rate of T(SH)2 degradation was ob-
served in the OE-TryS soluble cell protein extracts under conditions of
ex vivo flux determination, it was hypothesized that the unaltered
T(SH)2 levels in the OE-TryS1 cells could be due to an active T(SH)2
synthesis and degradation. This is supported by the previously reported
in vitro TryS amidase activity [41]. It is clear that further experimental
analyses in intact cells are required to assess that hypothesis, which
however, are beyond the main objective of the present study. Moreover,
T(SH)2 degradation was not detected in Wt and mock parasites, which
have wild-type TryS levels, ruling out any physiologically relevant
meaning for T(SH)2 degradation.
Finally, the predicted control exerted by CysT depended on the
availability of external Cys surrounding the parasite; the flux control
could be low for the intracellular parasite stages in the mammalian
cells, since higher Cys concentration than in blood can be found in the
cytosol of human host cells [42]. However, further experimentation is
required to establish the control of the Cys supplying reactions (such as
Cys transport and other metabolic pathways like de novo Cys synthesis
and trans-sulfuration) on T(SH)2 synthesis.
4.2. In silico and ex vivo flux control coefficients of the T(SH)2 –dependent
peroxide reduction pathway
The flux control distribution analysis by in vitro reconstitution of the
pathway with the recombinant enzymes previously reported by our
group [14] indicated that both TXN1 and TXNPx showed flux-control
coefficients of 1.0, whereas that of TryR was 0.2. In that experimental
setting, the sum of the flux control coefficients was close to 2, not one as
implied by the ‘classical’ summation theorem of MCA. The explanation
is that, unlike canonical metabolic pathways, this is an electron-transfer
pathway in which each individual redox reaction (process) compulso-
rily involves two enzymes, leading to a stoichiometry of one reaction/
two enzymes (and second-order dependence reaction on enzyme con-
centration) instead of the usual one reaction/one enzyme (and first-
order reaction dependence on enzyme concentration). Therefore, the
sum of the enzymes’ flux control coefficients on the transfer of groups
such as in redox pathways must be added to the sum of two, whilst the
sum of the flux control coefficients on the whole process of peroxide
reduction remains to be one (the pathway flux maintains a first-order
dependence on enzyme activities) [43]. Kinetic modeling of the redox
pathway reported here for the first time, allowed to obtain the CJai on
the peroxide reduction process, enabling to dissect CJai values of
0.11–0.16 for TryR, 0.64–0.73 for TXN1 and 0.17–0.2 for TXNPx, re-
spectively, considering that the sum of all CJai must add up to 1.0. These
in silico predicted values were in agreement with those obtained here by
titration of the activity in the parasites, whose CJai values were 0.73 and
0.15 for TXN1 and TryR, respectively. Moreover, overexpression of
TXN1 but not of TryR led to steady increases in the pathway flux, which
agreed with the high control attained by TXN1. Therefore, variations in
Fig. 5. In vitro infection capacity. (A) Percentage of infected
cells at 18 hpi. (B) number of intracellular amastigotes per
infected cell. (C) Trypomastigotes bursting compared to
mock cells at 4 and 5 dpi . Results are the mean ± SD of
three experiments each started from independent primary
infections with epimastigotes, except for C in which n = 2
but the difference in the values from the two experiments
was less than 30%. **p < 0.01, *p < 0.05 Student's t-test
for non-paired samples versus mock.
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TryR activity do not change the hydroperoxide reduction flux, but
variations in TXN1 do, hence, demonstrating that TXN1 has high
pathway control. Regarding TXNPx overexpression in the parasites, this
was not addressed in this work; however, in a mixed reconstituted
system using soluble cell protein extracts of mock and WT cells the ex
vivo peroxide reduction flux was titrated with recombinant TXNPx. The
CJai predicted by this strategy was similarly high to that of TXN1. This
result suggested that the control of the flux is shared equally by both
TXN1 and TXNPx.
TXN1 and TXNPx are abundant proteins in trypanosomatids (1–6%
of the total cellular protein) [20,44,45]. In T. cruzi the values calculated
by activity were 0.1% and 1% for TXN1 and TXNPx, respectively,
whereas the TryR protein content was 0.02% [14]. Reduction of TXN1
by T(SH)2 is the step with the lowest catalytic efficiency in the TXN-
dependent peroxide reduction pathway [14,45], which may explain the
high control that TXN1 exerts on the pathway flux. Certainly, TXNPx
overexpression prompts increased resistance to peroxides [19,39] and
infective stages overexpress this enzyme [20,21]. However, in these
reports TXN1 was not evaluated and higher TXN1-TXNPx stoichio-
metric coupling may favor higher peroxide reduction fluxes. On the
other hand, despite its lower protein content, TryR exhibited a com-
paratively high activity in the cells and high catalytic efficiency, as well
as lack of regulatory properties, which led to a low controlling enzyme.
It should be also emphasized that the kinetic properties of the en-
zymes, analyzed separately, reveal little about how and by which steps
the pathway is controlled. However, when all pathway enzymes (i.e.
with the content of active enzyme in the cells) are allowed to interact
with each other and with all ligands (in their physiological concentra-
tion ranges), the most controlling steps can be identified and the control
mechanisms clearly emerge. Such controlling enzymes can be now
proposed as very attractive targets for therapeutic intervention, since
their low inhibition can have the greatest negative effect in the pathway
flux and metabolite levels [23].
4.3. Fluxes and resistance to hydroperoxides and anti-chagasic compounds
Wt and mock cells exhibited ex vivo hydroperoxide reduction fluxes
of ≈11 nmol/min x mg soluble cell protein which is similar to those
reported for intact cells of the T. cruzi Y strain (3.3–12.9H2O2 nmol/min
x mg cell protein) [46]. Remarkably, these maximal outputs of peroxide
reduction values were one order of magnitude higher than those of the
T(SH)2 synthesis (0.6 ± 0.2 nmol/min x mg soluble cell protein) in Wt
cells. These results indicated that there was a 20-fold lower maximal
output of de novo T(SH)2 synthesis versus its usage for peroxide reduc-
tion. In consequence, the peroxide detoxification pathway, with a
highly active and efficient enzymatic machinery, seems to function
during immediate and acute (short-term) responses to oxidants,
whereas changes in the T(SH)2 synthesis flux are expected to have their
metabolic effect after a longer period of time upon the insult (long-term
response).
TXN1 down-regulation in T. brucei causes growth arrest and in-
creased sensitivity to H2O2 [47,48]. So far, there are no reports on the
effects of TXN1 overexpression in trypanosomatids. Remarkably, our
results showed for the first time that overexpression of TXN1 induced
higher resistance to this peroxide (Fig. 4). Furthermore, the OE-TryR
cells also showed enhanced H2O2 resistance despite TryR having low
control on the flux. As OE-TryR epimastigotes showed no changes in the
TXN1 and TXNPx activities that could contribute to the peroxide re-
sistance, the effect was probably due to the two orders of magnitude
higher TryR activity compared to the other OE-parasites. On the other
hand, no increased H2O2 resistance was observed in the OE-γECS and
OE-TryS epimastigotes. The lack of resistance in our OE-TryS epimas-
tigotes contrasts with the result obtained by others [36], where higher
(70%) H2O2 resistance on epimastigotes growth was found when TryS
was overexpressed. However, in that study the activities of TryR, TXN
and TXNPx were not assessed to determine that they were not changed.
Furthermore, our results with overexpressing TXN1 (≈10-fold)
were similar in terms of hydroperoxide resistance to those reported
when TXNPx was overexpressed [19,20,39], where the authors found
that 2.5-fold TXNPx overexpression increased by 50% the epimastigotes
viability exposed to H2O2 and helped the cells to contend with ONOO−.
A plausible explanation is that both enzymes interact tightly and
function in channeling, with TXN1 being the only reducing partner for
TXNPx. However, the higher activity in the parasite and higher cata-
lytic efficiency of TXNPx will require higher levels of inhibition than
TXN1 to affect the peroxide reduction pathway. Thus, TXN1 (or TXN1-
TXNPx interaction) may be a better target in order to inhibit the anti-
oxidant machinery as well as many other processes in which TXN1 is
involved (e.g. DNA synthesis, polyamine metabolism, protein transla-
tion and degradation [11,49,50]). In this regard, a high throughput
screening of a library of compounds identified some compounds that
preferably inhibited TXN in the T. brucei peroxide reduction pathway
over its human counterpart thioredoxin. The compounds showed a se-
lectivity index>5 for bloodstream trypomastigotes versus HeLa cells
[51], rendering TXN1 as a suitable target for therapeutic intervention.
Regarding TryR, it was here demonstrated that its control on the
hydroperoxide reduction flux was low because it is one of the most
efficient enzymes of the pathway. Consistently, its overexpression in the
T cruzi Silvio strain showed no effect on the cell's hydroperoxide re-
duction capacity [40] and it has been demonstrated that, in order to
affect the redox homeostasis in T. brucei, TryR has to be decreased by
more than 90% of its wild-type level [52]. Therefore, TryR seems to be
a very difficult target for therapeutic intervention.
Remarkably, TXN1 overexpression induced increased resistance to
Bnz (in combination with BSO). The proposed mode of cytotoxic Bnz
action is adduct formation with thiol metabolites such as GSH, T(SH)2,
and other molecules, rather than ROS formation [53–55]. Our results
suggested that a small dithiol protein such as TXN1 may also provide
some protection to the parasite against Bnz (and BSO effects), a hy-
pothesis that needs to be further experimentally analyzed. In this re-
gard, it has been recently proposed that some small proteins such as
TXN or glutaredoxins (Grx) may contribute to the reduction of glu-
tathione disulfide (GSSG) in organisms lacking glutathione reductase
[56]. The authors found that reduction of GSSG directly by T(SH)2 is a
slow process, whereas it is faster when it is mediated by Grx and/or
TXN. If both proteins are present at the physiological concentrations
analyzed, the reduction is preferably performed by Grx (75%) rather
than by TXN (25%). Whether TXN overexpression could favor GSSG
reduction was not here evaluated.
4.4. Parasite infectivity
As intracellular parasite, oxidative stress is a major challenge for T.
cruzi, suggesting that its antioxidant enzymes may contribute to its
survival and persistence. In fact, some of the enzymes have been studied
during the infection process of the parasite in phagocytic and non-
phagocytic cells, showing their participation in survival, replication and
differentiation of the parasite, proposing them as virulent factors
[19–21]. Therefore, we determined the role of γECS, TryS, TryR and
TXN1 in the infection process of T. cruzi in non-phagocytic cells, since
only in these ones the pathogenesis of the disease is established. It has
been determined for some T. cruzi strains that replication within in vitro
cultured host cells occurs from 18-72 hpi [57]; for this reason and based
on some preliminary observations, the infection process was analyzed
over time by examining the percentage of infected cells at 18 hpi, as
well as the number of internal parasites at 18, 48 and 66 hpi. Also, the
trypomastigotes that burst into the extracellular medium were mon-
itored at 4 and 5 dpi.
At 18 hpi, OE-γECS trypomastigotes were more infective than Wt or
mock trypomastigotes (Fig. 5A), suggesting that this enzyme may
contribute to the invasion. These findings concur with those reported
for Leishmania infantum, where the inactivation of one allele of the γECS
Z. González-Chávez, et al. Redox Biology 26 (2019) 101231
12
genes showed decreased GSH and T(SH)2 contents and decreased sur-
vival inside activated macrophages [58], which in turn showed an in-
creased production of oxygen and nitrogen oxidative species. Moreover,
the γECS content also increased in natural antimony-resistant isolates of
L. donovani [59,60].
On the other hand, OE-TryS and OE-TryR trypomastigotes showed a
tendency to higher infectivity (Fig. 5A). It has been reported that TryS
(and TXNPx) are involved in infectivity in mouse models and cell cul-
tures; hence both enzymes have been proposed as virulence factors
[20,21]. These two enzymes have been also found overexpressed in (i)
T. cruzi acute vs. chronic Chagas disease isolates [61]; (ii) virulent vs.
attenuated strains; and (iii) in metacyclic trypomastigotes vs. epimas-
tigotes (independently of the strain virulence) [21]. In the present
work, correlation between TryS overexpression and infectivity was low,
most probably because of the side effects observed in the OE-clones. On
the other side, Piacenza et al. found no correlation between the TryR
protein content and degree of virulence in different T. cruzi strains [21];
moreover, Kelly et al. [40] also found no correlation between TryR
overexpression and peroxide resistance. Here, in contrast, OE-TryR
showed an increased capacity to cope with H2O2 (Fig. 4C) which could
contribute to the slight increased infectivity at 18 hpi (Fig. 5A). The
different results may be related to the higher overexpression level of 50-
fold attained in our OE-TryR clones in comparison to the 15-fold at-
tained in the transfectant of Kelly et al. study. Lastly, to the best of our
knowledge this is the first time that the correlation between TXN1 (the
electron donor of TXNPx) and infectivity was analyzed, finding a sta-
tistically non-significant correlation between its overexpression and the
capacity to infect cells at 18 hpi.
The different OE-parasites showed a similar capacity to transform
into amastigotes, because at 18 hpi all parasites exhibited the same
number of internal amastigotes (Fig. 5B). In turn, the internal parasites
showed similar capacity to replicate within the cell, at 48 and 66 hpi
(Fig. 5B). However, a remarkable finding emerged at 4 and 5 dpi, where
OE-TXN displayed a notorious increase in trypomastigotes bursting
(Fig. 5C). A possible explanation is that the OE-TXN amastigotes have a
higher differentiation rate to trypomastigotes; however, this hypothesis
has to be analyzed in more detail to understand how TXN could be
involved in this process.
5. Conclusion
The results of the present investigation allowed to identify by both
in silico and ex vivo experimentation that γECS and TXN1 are enzymes
with high control on the T(SH)2 synthesis and peroxide reduction
fluxes, respectively. TryS has a lower, but meaningful contribution to
the control due to its very low activity in the parasite; thus, a slight
inhibition of this enzyme may also negatively impact the pathway flux.
Then, when T(SH)2 metabolism is compromised by thiol-conjugating
drugs such as Bnz, high T(SH)2 or thiol-protein contents may confer
drug-resistance. Hence, to prevent parasite resistance against this type
of antichagasic drugs, γECS and TXN1 (and TryS) activities should be
blocked. Therefore, therapeutic targeting of γECS and TXN1 will more
severely affect parasite viability than intervention at other, lower-
controlling pathway steps which will require much higher levels of
inhibition. In addition, despite its lower control, TryS should be still
considered an adequate drug target since its specific inhibition will
affect both T(SH)2 synthesis and peroxide reduction pathways.
Furthermore, γECS and TXN may contribute at different levels of the
infection process, strengthening its proposal as drug targets.
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